Laboratory For High Throughput Screening And Early Drug Discovery High throughput screening (hts) remains a promising initial step in discovering novel lead compounds for cancer therapy, but its value is limited by the poor predictability of clinical. The nemours high throughput screening (hts) & drug discovery lab is one of only a few such facilities worldwide dedicated exclusively to technology development and drug discovery for rare childhood diseases underserved by current pharmaceutical development efforts.
High Throughput Screening Strategies In Drug Discovery Macmillan Group He was awarded a ph.d. in chemistry from penn state university in 1989, after which he moved to the boston area and worked in drug discovery for genzyme, enanta, arqule, and elixir. Current group reporting to dr. napper consists of an hts scientist lab manager with more than 20 years of experience in pharmaceutical and academic drug discovery, a postdoctoral fellow, a research associate, and a recent faculty appointee. in the summer undergraduate scholars join the group. Dr. andrew napper is executive director, head of automation and assay technologies at bristol myers squibb in princeton, nj. he studied at the university of oxford and penn state university before working in the boston area for genzyme, enanta, arqule, and elixir pharmaceuticals. Our lab provides molecular testing for genetic conditions, as well as genotyping for pharmacogenomics, allowing personalized drug choice and dosing. we develop tools and data platforms that integrate clinical data and biomedical research to support precision medicine and improve pediatric care.
High Throughput Screening In Drug Discovery Technology Networks Dr. andrew napper is executive director, head of automation and assay technologies at bristol myers squibb in princeton, nj. he studied at the university of oxford and penn state university before working in the boston area for genzyme, enanta, arqule, and elixir pharmaceuticals. Our lab provides molecular testing for genetic conditions, as well as genotyping for pharmacogenomics, allowing personalized drug choice and dosing. we develop tools and data platforms that integrate clinical data and biomedical research to support precision medicine and improve pediatric care. Dr. andrew napper studied at the university of oxford and penn state university before working in the boston area for genzyme, enanta, arqule, and elixir pharmaceuticals. while at elixir, he played a leading role in the discovery of selisistat (ex 527), which was licensed to siena biotech and progressed to phase ii clinical trials as a. The nemours high throughput screening (hts) & drug discovery lab is one of only a few such facilities worldwide dedicated exclusively to technology development and drug discovery for rare childhood diseases underserved by current pharmaceutical development efforts. The main focus of our work is to discover and develop new drugs to treat childhood leukemia. in particular, we are focused on mll rearranged leukemia, which strikes mainly infants and young children. Andrew napper, ph.d, recently joined the research team at the nemours center for childhood cancer research to establish its high throughput screening and drug discovery laboratory. the goal of napper’s work is to discover new drugs for childhood cancers.
Highthroughput Screening Speeds Up Drug Discovery Process Concept Drug Dr. andrew napper studied at the university of oxford and penn state university before working in the boston area for genzyme, enanta, arqule, and elixir pharmaceuticals. while at elixir, he played a leading role in the discovery of selisistat (ex 527), which was licensed to siena biotech and progressed to phase ii clinical trials as a. The nemours high throughput screening (hts) & drug discovery lab is one of only a few such facilities worldwide dedicated exclusively to technology development and drug discovery for rare childhood diseases underserved by current pharmaceutical development efforts. The main focus of our work is to discover and develop new drugs to treat childhood leukemia. in particular, we are focused on mll rearranged leukemia, which strikes mainly infants and young children. Andrew napper, ph.d, recently joined the research team at the nemours center for childhood cancer research to establish its high throughput screening and drug discovery laboratory. the goal of napper’s work is to discover new drugs for childhood cancers.
Drug Discovery Explained Episode 2 The main focus of our work is to discover and develop new drugs to treat childhood leukemia. in particular, we are focused on mll rearranged leukemia, which strikes mainly infants and young children. Andrew napper, ph.d, recently joined the research team at the nemours center for childhood cancer research to establish its high throughput screening and drug discovery laboratory. the goal of napper’s work is to discover new drugs for childhood cancers.
Comments are closed.